Navigation Links
Peach genome offers insights into breeding strategies for biofuels crops
Date:3/24/2013

y/JGI-Plants), and develop methods for improving plant biomass yield for biofuels.

"One gene we're interested in is the so-called "evergreen" locus in peaches, which extends the growing season," said Daniel Rokhsar, DOE JGI Eukaryotic Program head under whose leadership sequencing of the peach genome began back in 2007. "In theory, it could be manipulated in poplar to increase the accumulation of biomass."

The publication comes three years after the International Peach Genome Consortium publicly released the draft assembly of the annotated peach genome on the DOE JGI Plant portal Phytozome.net and on other websites. The decision to sequence the peach genome was first announced during the 2007 Plant and Animal Genome XI Conference. Learn more about poplar and DOE JGI Plant Flagship Genomes at http://genome.jgi.doe.gov/programs/plants/flagship_genomes.jsf.

In the United States, the Initiative was funded by the U.S. Department of Energy Office of Science and led by researchers at the DOE JGI, The HudsonAlpha Institute for Biotechnology, Clemson University, North Carolina State University, and Washington State University. Additional support was contributed by U.S. Department of Agriculture and by the Energy Biosciences Institute, of the University of California, Berkeley, who supported senior author Therese Mitros. The Italian government also supported this international effort, including the work of first author Ignazio Verde of the Fruit Tree Research Centre/Agricultural Research Council in Rome, Italy. Contributions were also made from research institutes in Chile, Spain, and France.


'/>"/>

Contact: David Gilbert
degilbert@lbl.gov
925-296-5643
DOE/Joint Genome Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clemson University researchers: What happens to peaches when the chill is gone?
2. Leading evolutionary scientist to discuss how genome of bacteria has evolved
3. Darwin in the genome
4. Analysis of stickleback genome sequence catches evolution in action
5. Athletic frogs have faster-changing genomes
6. PNAS: Precise molecular surgery in the plant genome
7. BGI and Aspera collaborate on high-speed data exchange to advance genome research
8. Researchers announce GenomeSpace environment to connect genomic tools
9. UC Santa Cruz builds national data center for cancer genome research
10. BGI reports the completed sequence of foxtail millet genome
11. Relative reference: Foxtail millet offers clues for assembling the switchgrass genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2015)... 2015 IriTech, a leading iris based identity ... Texas Instruments Design Network, announced today that the Chief ... IriShield USB MK2120U device during a launching event of ... The iris scanner is manufactured by ... India through its Indian partner, ...
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... of the "Access Control Market by Product, Application ... 2020" report to their offering. , ... expected to reach $10.4 billion by 2020, with an ... market report covers the products types such as contact ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... people usually don,t die from a heart attack. But the ... succumb to congestive heart failure, the most common cause of ... hope for achieving what the body can,t do: mending broken ... built a scaffold that supports the growth and integration of ...
... -- A microscopic gene may play a gigantic role when ... to one Kansas State University research team. The team ... Disintegrin and Metalloprotease family, or ADAM family, and its role ... is a good guy or a bad guy in breast ...
... against cancerous tumors, radiation therapy often harms healthy tissue as ... of Tel Aviv University,s Department of Biomedical Engineering is developing ... and minimal damage to surrounding tissue. His innovative ... uses heat to kill the tumor cells but leaves ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3K-State research team investigates mutated gene's role in breast cancer 2A 'magnetic' solution to identify and kill tumors 2
(Date:3/30/2015)... March 30, 2015    Intrexon Corporation ... biology, and Merck Serono, the biopharmaceutical business of ... today announced an exclusive strategic collaboration and license ... T-cell (CAR-T) cancer therapies. This collaboration advances Merck ... that modulate the immune system,s natural ability to ...
(Date:3/30/2015)... N.J. , March 30, 2015  Naldemedine, ... under development by Shionogi & Co., Ltd., met ... III study (COMPOSE I) for the treatment of ... non-cancer pain receiving opioid therapy. Study results showed ... statistically significantly improved the frequency of spontaneous bowel ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) fertilizers ... high prices in 2008. However, the situation has stabilised ... gaining momentum now. , To date, the world annual ... thousand tonnes. No considerable growth was registered in the ... during 2012-2013, registering 11% growth as against the period ...
Breaking Biology Technology:Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3
... , SUNNYVALE, Calif., July 23 FlowCardia, ... the treatment of chronic total occlusions (CTOs), today announced the appointment ... previously held the position of Executive VP, Sales and Marketing at ... including the last 2 years at FlowCardia. , ...
... , , , ... with Moderate to Severe Post-Operative Pain , ... QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation ... and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV ...
... , ST. LOUIS, July 23 Sigma-Aldrich Corporation ... Technology company, reported second quarter 2009 diluted EPS of $0.68 compared ... six months ended June 30, 2009, reported diluted EPS was $1.36, ... months of 2008. Excluding the negative impact of currency, EPS ...
Cached Biology Technology:FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer 2QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy 2QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 2Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 4Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 5Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 6Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 7Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 8Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 9Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 10Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 11Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 12Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 13Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 14Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 15Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 16Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 17
Request Info...
CoverWell imaging chamber gasket with adhesive, one chamber, 20 mm diameter, 1.0 mm deep *set of 40* Cell Biology Imaging Tools and Accessories Microscope Slide Accessories...
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
... as 10X concentrated solutions. REact Buffer SetConsists of ... REact buffers and one 250 microl vial of ... ml vials of REact 1 Buffer four 1 ... ml vials of REact 3 Buffer and four ...
Biology Products: